Avaliação por imagem das lesões isoladas do III par craniano

Este trabalho tem por objetivo fazer uma revisão da anatomia e das principais doenças do III par craniano, demonstrando-as através de estudos por imagem, com ênfase em ressonância magnética. Os métodos de imagem são peça fundamental na avaliação de pacientes com suspeita de lesão do nervo oculomotor, uma vez que o quadro clínico é freqüentemente inespecífico e a gama de doenças que podem acometê-lo é bastante ampla. Realizamos também breve levantamento da literatura.

Verificação da atividade condilar em pacientes com padrão esquelético classe III por intermédio da cintilografia óssea

OBJETIVO: Utilizar a cintilografia óssea facial para identificar o crescimento esquelético mandibular, através do metabolismo ósseo condilar de indivíduos com crescimento craniofacial equilibrado, e compará-lo à atividade condilar daqueles com crescimento mandibular excessivo. MATERIAIS E MÉTODOS: Quarenta e sete indivíduos, de ambos os sexos, entre 18 e 28 anos de idade, foram divididos em grupo controle - classe I (n = 13) - e grupo caso - classe III (n = 34). As imagens foram obtidas duas horas após injeção intravenosa de 200 µCi/kg de 99mTc-MDP. Foram realizadas incidências laterais do crânio e posterior da coluna lombar e a taxa de contagem foi determinada pela obtenção da média de contagem dos côndilos e da quarta vértebra lombar utilizando 300.000 contagens. RESULTADOS: Não foram encontradas captações condilares assimétricas em ambos os grupos, e apesar da ausência de significância estatística, os valores médios de captação condilar foram maiores no grupo caso. CONCLUSÃO: A média de captação aumentada indicou maior metabolismo ósseo condilar nos indivíduos classe III, sugerindo um provável crescimento mandibular residual. Mais estudos estão sendo realizados para aumentar esta amostragem.

La crisis del segle III a l’àrea compresa entre Tarraco i Saguntum: aproximació a partir de les dades arqueològiques

The purpose of this work is to evaluate the possible impact of the so-called “crisis of the 3rd century” in the area between Tarraco (Tarragona) and Saguntum (Sagunt), currently corresponding to the southern limit of Catalonia and the north of Valencia, which during the Roman era made up the southernmost part of the conventus Tarraconensis. The processes of change experienced in rural settlements and cities between the Severan dynasty and the beginning of the tetrarchy are analyzed, and the importance of the city-country relationship is examined to explain these changes. The extent of the Frankish invasion during of the Gallic period, initially substantiated by sources and now by archaeological evidence, is discussed. The study of coin hoards (treasures and deposits) from the second half of the 3rd century, found in abundance in this area, is a very interesting aspect of this topic. In addition, a quantitative approach is used to study the population changes experienced as a result of the rural settlement of this area during the 3rd century, between the High and the Low Empires.

Redox Signaling by the RNA Polymerase III TFIIB-Related Factor Brf2.

TFIIB-related factor 2 (Brf2) is a member of the family of TFIIB-like core transcription factors. Brf2 recruits RNA polymerase (Pol) III to type III gene-external promoters, including the U6 spliceosomal RNA and selenocysteine tRNA genes. Found only in vertebrates, Brf2 has been linked to tumorigenesis but the underlying mechanisms remain elusive. We have solved crystal structures of a human Brf2-TBP complex bound to natural promoters, obtaining a detailed view of the molecular interactions occurring at Brf2-dependent Pol III promoters and highlighting the general structural and functional conservation of human Pol II and Pol III pre-initiation complexes. Surprisingly, our structural and functional studies unravel a Brf2 redox-sensing module capable of specifically regulating Pol III transcriptional output in living cells. Furthermore, we establish Brf2 as a central redox-sensing transcription factor involved in the oxidative stress pathway and provide a mechanistic model for Brf2 genetic activation in lung and breast cancer.

Severity and burden of partial-onset seizures in a phase III trial of eslicarbazepine acetate.

OBJECTIVE: The objective of this study was to compare posttreatment seizure severity in a phase III clinical trial of eslicarbazepine acetate (ESL) as adjunctive treatment of refractory partial-onset seizures. METHODS: The Seizure Severity Questionnaire (SSQ) was administered at baseline and posttreatment. The SSQ total score (TS) and component scores (frequency and helpfulness of warning signs before seizures [BS]; severity and bothersomeness of ictal movement and altered consciousness during seizures [DS]; cognitive, emotional, and physical aspects of postictal recovery after seizures [AS]; and overall severity and bothersomeness [SB]) were calculated for the per-protocol population. Analysis of covariance, adjusted for baseline scores, estimated differences in posttreatment least square means between treatment arms. RESULTS: Out of 547 per-protocol patients, 441 had valid SSQ TS both at baseline and posttreatment. Mean posttreatment TS for ESL 1200mg/day was significantly lower than that for placebo (2.68 vs 3.20, p<0.001), exceeding the minimal clinically important difference (MCID: 0.48). Mean DS, AS, and SB were also significantly lower with ESL 1200mg/day; differences in AS and SB exceeded the MCIDs. The TS, DS, AS, and SB were lower for ESL 800mg/day than for placebo; only SB was significant (p=0.013). For both ESL arms combined versus placebo, mean scores differed significantly for TS (p=0.006), DS (p=0.031), and SB (p=0.001). CONCLUSIONS: Therapeutic ESL doses led to clinically meaningful, dose-dependent reductions in seizure severity, as measured by SSQ scores. CLASSIFICATION OF EVIDENCE: This study presents Class I evidence that adjunctive ESL (800 and 1200mg/day) led to clinically meaningful, dose-dependent seizure severity reductions, measured by the SSQ.

ADHD candidate gene (DRD4 exon III) affects inhibitory control in a healthy sample.

Background Dopamine is believed to be a key neurotransmitter in the development of attention-deficit/ hyperactivity disorder (ADHD). Several recent studies point to an association of the dopamine D4 receptor (DRD4) gene and this condition. More specifically, the 7 repeat variant of a variable number of tandem repeats (VNTR) polymorphism in exon III of this gene is suggested to bear a higher risk for ADHD. In the present study, we investigated the role of this polymorphism in the modulation of neurophysiological correlates of response inhibition (Go/Nogo task) in a healthy, high-functioning sample. Results Homozygous 7 repeat carriers showed a tendency for more accurate behavior in the Go/Nogo task compared to homozygous 4 repeat carriers. Moreover, 7 repeat carriers presented an increased nogo-related theta band response together with a reduced go-related beta decrease. Conclusions These data point to improved cognitive functions and prefrontal control in the 7 repeat carriers, probably due to the D4 receptor's modulatory role in prefrontal areas. The results are discussed with respect to previous behavioral data on this polymorphism and animal studies on the impact of the D4 receptor on cognitive functions.

Angioplastia infra-inguinal em pacientes com isquemia crítica grau III, categoria 5 de Rutherford

OBJETIVO: Analisar a eficiência da angioplastia primária infra-inguinal como método de salvamento de membros em pacientes portadores de lesões tróficas por isquemia crítica. MATERIAIS E MÉTODOS: Foram analisados 36 pacientes submetidos a angioplastias primárias sem stent. Todos os pacientes apresentavam isquemia crítica com lesão trófica - grau III, categoria 5 de Rutherford -, sendo 17 lesões na artéria femoral superficial, 16 na artéria poplítea e 51 em artérias da perna, totalizando 84 angioplastias. Foram analisadas também as prevalências em relação a sexo, membro afetado, idade e principais comorbidades, sendo tecidas considerações técnicas sobre os procedimentos, assim como os materiais utilizados. RESULTADOS: Considerou-se sucesso quando a lesão trófica que motivou a angioplastia cicatrizou, ou o nível de amputação limitou-se a artelhos ou ao antepé, sem ter havido necessidade de procedimento cirúrgico de reconstituição do fluxo sanguíneo (bypass), independentemente de tempo, drogas associadas e números de desbridamentos realizados. CONCLUSÃO: As angioplastias no segmento femoropoplíteo e infrapoplíteo são procedimentos de elevado sucesso técnico, baixa morbidade e mortalidade, constituindo-se procedimento eficaz em pacientes com isquemia crítica de membro inferior.

Symphonie-Fantastique op. 4 [!], III Scène aux champs

Soitinnus: piano, 4-kät.

Randomised, multicentre, phase III, open-label study of alectinib vs crizotinib in treatment-naïve anaplastic lymphoma kinase (ALK)-positive advanced NSCLC (ALEX study).

Background: In ∼5% of advanced NSCLC tumours, ALK tyrosine kinase is constitutively activated after translocation of ALK. ALK+ NSCLC was shown to be highly sensitive to the first approved ALK inhibitor, crizotinib. However, all pts eventually relapse on crizotinib mainly due to secondary ALK mutations/amplification or CNS metastases. Alectinib is a highly selective, potent, oral next-generation ALK inhibitor. Clinical phase II alectinib data in 46 crizotinib-naïve pts with ALK+ NSCLC reported an objective response rate (ORR) of 93.5% and a 1-year progression-free rate of 83% (95% CI: 68-92) (Inoue et al. J Thorac Oncol 2013). CNS activity was seen: of 14 pts with baseline brain metastasis, 11 had prior CNS radiation, 9 of these experienced CNS and systemic PFS of >12 months; of the 3 pts without prior CNS radiation, 2 were >15 months progression free. Trial design: Randomised, multicentre, phase III, open-label study in pts with treatment-naïve ALK+ advanced, recurrent, or metastatic NSCLC. All pts must provide pretreatment tumour tissue to confirm ALK rearrangement (by IHC). Pts (∼286 from ∼180 centres, ∼30 countries worldwide) will be randomised to alectinib (600mg oral bid, with food) or crizotinib (250mg oral bid, with/without food) until disease progression (PD), unacceptable toxicity, withdrawal of consent, or death. Stratification factors are: ECOG PS (0/1 vs 2), race (Asian vs non-Asian), baseline CNS metastases (yes vs no). Primary endpoint: PFS by investigators (RECIST v1.1). Secondary endpoints: PFS by Independent Review Committee (IRC); ORR; duration of response; OS; safety; pharmacokinetics; quality of life. Additionally, time to CNS progression will be evaluated (MRI) for the first time in a prospective randomised NSCLC trial as a secondary endpoint. Pts with isolated asymptomatic CNS progression will be allowed to continue treatment beyond documented progression until systemic PD and/or symptomatic CNS progression, according to investigator opinion. Time to CNS progression will be retrospectively assessed by the IRC using two separate criteria, RECIST and RANO. Further details: ClinicalTrials.gov (NCT02075840). Disclosure: T.S.K. Mok: Advisory boards: AZ, Roche, Eli Lilly, Merck Serono, Eisai, BMS, AVEO, Pfizer, Taiho, Boehringer Ingelheim, Novartis, GSK Biologicals, Clovis Oncology, Amgen, Janssen, BioMarin; board of directors: IASLC; corporate sponsored research: AZ; M. Perol: Advisory boards: Roche; S.I. Ou: Consulting: Pfizer, Chugai, Genentech Speaker Bureau: Pfizer, Genentech, Boehringer Ingelheim; I. Bara: Employee: F. Hoffmann-La Roche Ltd; V. Henschel: Employee and stock: F. Hoffmann-La Roche Ltd.; D.R. Camidge: Honoraria: Roche/Genentech. All other authors have declared no conflicts of interest.

The awr gene family encodes a novel class of Ralstonia solanacearum type III effectors displaying virulence and avirulence activities

We present here the characterization of a new gene family, awr, found in all sequenced Ralstonia solanacearum strains and in other bacterial pathogens. We demonstrate that the five paralogues in strain GMI1000 encode type III-secreted effectors and that deletion of all awr genes severely impairs its capacity to multiply in natural host plants. Complementation studies show that the AWR (alanine-tryptophanarginine tryad) effectors display some functional redundancy, although AWR2 is the major contributor to virulence. In contrast, the strain devoid of all awr genes (¿awr1-5) exhibits enhanced pathogenicity on Arabidopsis plants. A gain-of-function approach expressing AWR in Pseudomonas syringae pv. tomato DC3000 proves that this is likely due to effector recognition, because AWR5 and AWR4 restrict growth of this bacterium in Arabidopsis. Transient overexpression of AWR in nonhost tobacco species caused macroscopic cell death to varying extents, which, in the case of AWR5, shows characteristics of a typical hypersensitive response. Our work demonstrates that AWR, which show no similarity to any protein with known function, can specify either virulence or avirulence in the interaction of R. solanacearum with its plant hosts.

Final results of the SAKK 16/00 trial: a randomized phase III trial comparing neoadjuvant chemoradiation to chemotherapy alone in stage IIIA/N2 non-small cell lung cancer (NSCLC).

Aim: One standard option in the treatment of stage IIIA/N2 NSCLC is neoadjuvant chemotherapy followed by surgery. We investigated in a randomized trial whether the addition of neoadjuvant radiotherapy would improve the outcome. Here we present the final results of this study. Methods: Patients (pts.) with pathologically proven, resectable stage IIIA/N2 NSCLC, performance status 0-1, and adequate organ function were randomized 1:1 to chemoradiation (CRT) with 3 cycles of neoadjuvant chemotherapy (cisplatin 100 mg/m2 and docetaxel 85 mg/m2 d1, q3weeks) followed by accelerated concomitant boost radiotherapy (RT) with 44 Gy in 22 fractions in 3 weeks, or neoadjuvant chemotherapy alone (CT), with subsequent surgery for all pts. The primary endpoint was event-free survival (EFS). Results: 232 pts. were randomized in 23 centers, the median follow-up was 53 months. Two thirds were men, median age was 60 years (range 37-76). Histology was squamous cell in 33%, adenocarcinoma in 43%. Response rate to CRT was 61% vs. 44% with CT. 85% of all pts. underwent surgery, 30-day postoperative mortality was 1%. The rate of complete resection was 91% (CRT) vs. 81% (CT) and the pathological complete remission (pCR) rate was 16% vs. 12%. The median EFS was 13.1 months (95% CI 9.9 - 23.5) for the CRT group vs. 11.8 months (95% CI 8.4 - 15.2) in the CT arm (p 0.665). The median overall survival (OS) with CRT was 37.1 months (95% CI 22.6 -50), with CT 26.1 months ( 95% CI 26.1 - 52.1, p 0.938). The local failure rate was 23% in both arms. In the CT arm 12 pts. were given postoperative radiotherapy (PORT) for R1 resection, 6 pts. received PORT in violation of the protocol. Pts. with a pCR, mediastinal downstaging to ypN0/1 and complete resection had a better outcome. Toxicity of chemotherapy was substantial, especially febrile neutropenia was common, whereas RT was well tolerated. Conclusions: This is the first completed phase III trial to evaluate the role of induction chemoradiotherapy and surgery, in comparison to neoadjuvant CT alone followed by surgery. RT was active, it increased response, complete resection and pCR rates. However, this failed to translate into an improvement of local control, EFS or OS. Notably, surgery after induction treatment was safe, including pneumonectomy. The overall survival rates of our neoadjuvant regimen are very encouraging, especially for a multicenter setting. Disclosure: M. Pless: Advisory Board for Sanofi; R. Cathomas: Advisory Board Sanofi D.C. Betticher: Advisory Board Sanofi. All other authors have declared no conflicts of interest.

Verifique sus conocimientos sobre las exploraciones complementarias (III)

Ésta es la tercera entrega de una serie sobre las pruebas complementarias que se inició en el ejemplar de Nursing2007 de abril. Nuestra intención es completar el apartado sobre el esqueleto óseo. La importancia de la radiología convencional osteoarticular y su uso generalizado hacen que consideremos indicado profundizar en algunos aspectos ya mencionados en la anterior entrega e introducir algunos conceptos nuevos que nos permitan conocer a fondo este apartado. Una vez más recordamos la importancia que para los diplomados/as en enfermería tiene la posibilidad de conocer estas exploraciones, y más en el caso que nos ocupa, por lo habitual del contacto con estas técnicas en la práctica diaria de muchos de nosotros. El objetivo es conocer la preparación y las características generales de la prueba, así como las curas posteriores a ella para satisfacer las necesidades del paciente durante el proceso diagnóstico. En nuestro entrenamiento para aprender a identificar las imágenes es interesante ayudarse de personas que, como los técnicos especialistas en radiología y los médicos especialistas radiólogos, visualizan continuamente exploraciones radiológicas y nos pueden ayudar a aplicar los conocimientos y las pautas de interpretación de imágenes radiológicas que exponemos en esta serie.

Verifique sus conocimientos sobre las exploraciones complementarias (III)

Ésta es la tercera entrega de una serie sobre las pruebas complementarias que se inició en el ejemplar de Nursing2007 de abril. Nuestra intención es completar el apartado sobre el esqueleto óseo. La importancia de la radiología convencional osteoarticular y su uso generalizado hacen que consideremos indicado profundizar en algunos aspectos ya mencionados en la anterior entrega e introducir algunos conceptos nuevos que nos permitan conocer a fondo este apartado. Una vez más recordamos la importancia que para los diplomados/as en enfermería tiene la posibilidad de conocer estas exploraciones, y más en el caso que nos ocupa, por lo habitual del contacto con estas técnicas en la práctica diaria de muchos de nosotros. El objetivo es conocer la preparación y las características generales de la prueba, así como las curas posteriores a ella para satisfacer las necesidades del paciente durante el proceso diagnóstico. En nuestro entrenamiento para aprender a identificar las imágenes es interesante ayudarse de personas que, como los técnicos especialistas en radiología y los médicos especialistas radiólogos, visualizan continuamente exploraciones radiológicas y nos pueden ayudar a aplicar los conocimientos y las pautas de interpretación de imágenes radiológicas que exponemos en esta serie.